Milestone Pharmaceuticals (MIST) Competitors $0.70 -0.05 (-7.24%) Closing price 04:00 PM EasternExtended Trading$0.70 +0.01 (+0.91%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST vs. RGNX, SIGA, ERAS, HUMA, SNDL, PRTC, UPB, RNAC, KMDA, and TRDAShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include REGENXBIO (RGNX), SIGA Technologies (SIGA), Erasca (ERAS), Humacyte (HUMA), SNDL (SNDL), PureTech Health (PRTC), Upstream Bio (UPB), Cartesian Therapeutics (RNAC), Kamada (KMDA), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. REGENXBIO SIGA Technologies Erasca Humacyte SNDL PureTech Health Upstream Bio Cartesian Therapeutics Kamada Entrada Therapeutics REGENXBIO (NASDAQ:RGNX) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, community ranking, valuation, media sentiment, analyst recommendations, dividends and earnings. Does the MarketBeat Community believe in RGNX or MIST? REGENXBIO received 358 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. However, 69.11% of users gave Milestone Pharmaceuticals an outperform vote while only 65.53% of users gave REGENXBIO an outperform vote. CompanyUnderperformOutperformREGENXBIOOutperform Votes44365.53% Underperform Votes23334.47% Milestone PharmaceuticalsOutperform Votes8569.11% Underperform Votes3830.89% Is RGNX or MIST more profitable? Milestone Pharmaceuticals has a net margin of 0.00% compared to REGENXBIO's net margin of -283.19%. REGENXBIO's return on equity of -70.65% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-283.19% -70.65% -41.68% Milestone Pharmaceuticals N/A -151.82%-49.85% Do insiders and institutionals hold more shares of RGNX or MIST? 88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 13.1% of REGENXBIO shares are owned by insiders. Comparatively, 9.9% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend RGNX or MIST? REGENXBIO presently has a consensus price target of $32.78, indicating a potential upside of 415.62%. Milestone Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 2,381.75%. Given Milestone Pharmaceuticals' higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than REGENXBIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Milestone Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to RGNX or MIST? In the previous week, Milestone Pharmaceuticals had 13 more articles in the media than REGENXBIO. MarketBeat recorded 16 mentions for Milestone Pharmaceuticals and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.11 beat Milestone Pharmaceuticals' score of -0.14 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Pharmaceuticals 0 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, RGNX or MIST? Milestone Pharmaceuticals has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$83.33M3.82-$263.49M-$4.61-1.38Milestone Pharmaceuticals$1M36.55-$59.69M-$0.68-1.01 Which has more volatility and risk, RGNX or MIST? REGENXBIO has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. SummaryREGENXBIO and Milestone Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.81M$6.56B$5.40B$7.28BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-0.856.8522.8817.61Price / Sales36.55194.91357.3086.64Price / CashN/A65.6738.1634.64Price / Book1.375.746.323.86Net Income-$59.69M$142.37M$3.21B$247.18M7 Day Performance-22.16%-9.71%-6.89%-6.27%1 Month Performance-58.23%-12.66%-1.87%-8.87%1 Year Performance-60.86%-16.65%4.62%-6.18% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals1.7789 of 5 stars$0.70-7.2%$17.00+2,343.6%-57.4%$37.12M$1M-0.8630Analyst DowngradeAnalyst RevisionGap DownHigh Trading VolumeRGNXREGENXBIO4.4298 of 5 stars$8.70+5.6%$33.88+289.4%-67.1%$435.75M$83.33M-1.73370Gap DownSIGASIGA Technologies2.5474 of 5 stars$5.98+6.6%N/A-47.3%$427.19M$138.72M4.9840Options VolumeNews CoveragePositive NewsGap DownERASErasca3.5875 of 5 stars$1.49-2.6%$4.80+222.1%-44.2%$421.26MN/A-1.80120HUMAHumacyte2.0126 of 5 stars$3.32flat$13.71+313.1%-52.1%$417.85M$1.57M-2.48150Earnings ReportGap DownSNDLSNDL3.4875 of 5 stars$1.59+0.6%$3.63+128.0%-43.2%$417.81M$920.45M-5.13580Positive NewsGap DownPRTCPureTech Health1.1337 of 5 stars$17.30+3.5%$45.00+160.1%-33.0%$415.51M$3.33M0.00100Gap DownUPBUpstream BioN/A$7.70+1.0%$56.50+633.8%N/A$413.04M$2.37M0.0038Lockup ExpirationGap DownRNACCartesian Therapeutics2.0806 of 5 stars$15.94-0.7%$42.14+164.4%-16.1%$412.96M$38.91M-0.3064Gap DownKMDAKamada3.5777 of 5 stars$7.10+5.7%$14.67+106.6%+12.1%$408.11M$160.95M25.36360High Trading VolumeTRDAEntrada Therapeutics2.35 of 5 stars$10.80+3.0%$25.67+137.7%-41.9%$406.03M$210.78M6.79110Analyst RevisionGap Down Remove Ads Related Companies and Tools Related Companies RGNX Alternatives SIGA Alternatives ERAS Alternatives HUMA Alternatives SNDL Alternatives PRTC Alternatives UPB Alternatives RNAC Alternatives KMDA Alternatives TRDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIST) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MIST Stock Free MIST Stock Alerts